ReviewFrontiers in pharmacology2026
Targeting the Correa's cascade of gastric cancer: the potential role of phytochemicals and autophagy modulation.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) development follows a sequential and complex pathophysiological process known as Correa's cascade, progressing from chronic gastritis (active or inactive) to precancerous lesions (intestinal metaplasia (IM) and dysplasia) and ultimately to adenocarcinoma. Current GC therapies have limited efficacy and high recurrence rates. Autophagy, a cellular self-degradation mechanism that removes damaged or harmful components, plays a critical role in maintaining cellular homeostasis. Phytochemicals, owing to their low toxicity and multi-target pharmacological properties, exhibit anti-inflammatory, antimicrobial, antioxidant, and anticancer activities, and certain phytochemicals have shown potential in suppressing GC progression. In the inflammatory stage, metabolites such as berberine (an alkaloid) and chlorogenic acid (a phenolic acid) modulate autophagy by regulating the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway: upstream activation of PI3K leads to AKT phosphorylation, which subsequently inhibits the downstream autophagy-related genes Unc-51-like kinase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.